Lax S - Search Results

1

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.

Reiner-Concin A, Regitnig P, Dinges HP, Höfler G, Lax S, Müller-Holzner E, Obrist P, Rudas M. Reiner-Concin A, et al. Among authors: lax s. Pathol Oncol Res. 2008 Sep;14(3):253-9. doi: 10.1007/s12253-008-9079-z. Epub 2008 Aug 28. Pathol Oncol Res. 2008. PMID: 18752057 Free article.

2

Microsatellite analysis of breast carcinoma and corresponding local recurrences.

Regitnig P, Moser R, Thalhammer M, Luschin-Ebengreuth G, Ploner F, Papadi H, Tsybrovskyy O, Lax SF. Regitnig P, et al. J Pathol. 2002 Oct;198(2):190-7. doi: 10.1002/path.1193. J Pathol. 2002. PMID: 12237878

3

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.

Regitnig P, Reiner A, Dinges HP, Höfler G, Müller-Holzner E, Lax SF, Obrist P, Rudas M, Quehenberger F. Regitnig P, et al. Virchows Arch. 2002 Oct;441(4):328-34. doi: 10.1007/s00428-002-0646-5. Epub 2002 Sep 17. Virchows Arch. 2002. PMID: 12404057

4

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H. Moinfar F, et al. Cancer. 2003 Aug 15;98(4):703-11. doi: 10.1002/cncr.11532. Cancer. 2003. PMID: 12910513 Free article.

5

High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.

Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M. Pohl G, et al. Among authors: lax s. J Clin Oncol. 2003 Oct 1;21(19):3594-600. doi: 10.1200/JCO.2003.02.021. J Clin Oncol. 2003. PMID: 14512390

6

Bilateral carcinomas of the breast with local recurrence: analysis of genetic relationship of the tumors.

Regitnig P, Ploner F, Maderbacher M, Lax SF. Regitnig P, et al. Mod Pathol. 2004 May;17(5):597-602. doi: 10.1038/modpathol.3800089. Mod Pathol. 2004. PMID: 15017434 Free article.

7

The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.

Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H. Schippinger W, et al. Among authors: lax s. Oncol Rep. 2004 Jun;11(6):1331-6. Oncol Rep. 2004. PMID: 15138574

8

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.

Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF. Regitnig P, et al. J Pathol. 2004 Aug;203(4):918-26. doi: 10.1002/path.1592. J Pathol. 2004. PMID: 15258994

9

Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.

Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R. Filipits M, et al. Among authors: lax s. J Clin Oncol. 2005 Feb 20;23(6):1161-8. doi: 10.1200/JCO.2005.03.033. J Clin Oncol. 2005. PMID: 15718312

10

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Rudas M, et al. Among authors: lax s. Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122. Clin Cancer Res. 2008. PMID: 18347178 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page